Hennion & Walsh Asset Management Inc. Has $1.66 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Hennion & Walsh Asset Management Inc. grew its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 73.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,848 shares of the medical instruments supplier's stock after buying an additional 7,559 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.08% of LeMaitre Vascular worth $1,658,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in LMAT. CANADA LIFE ASSURANCE Co lifted its holdings in LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier's stock worth $1,472,000 after acquiring an additional 6,875 shares in the last quarter. Quantbot Technologies LP grew its position in shares of LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier's stock valued at $487,000 after purchasing an additional 6,669 shares during the period. Vanguard Group Inc. increased its stake in LeMaitre Vascular by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier's stock worth $87,914,000 after purchasing an additional 38,303 shares in the last quarter. Quadrature Capital Ltd lifted its stake in LeMaitre Vascular by 129.4% in the first quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier's stock valued at $1,484,000 after buying an additional 12,654 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier's stock valued at $3,697,000 after buying an additional 47,218 shares during the period. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

LMAT stock traded down $0.94 during mid-day trading on Friday, reaching $85.64. The company had a trading volume of 85,853 shares, compared to its average volume of 121,747. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of 51.28, a PEG ratio of 2.29 and a beta of 0.88. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $93.32. The stock has a 50 day simple moving average of $89.29 and a two-hundred day simple moving average of $82.25.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $55.85 million during the quarter, compared to analysts' expectations of $54.98 million. During the same period last year, the business earned $0.37 earnings per share. The firm's revenue was up 11.4% on a year-over-year basis. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.86 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were given a dividend of $0.16 per share. The ex-dividend date was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.75%. LeMaitre Vascular's dividend payout ratio (DPR) is 38.32%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the company's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LMAT shares. Barrington Research restated an "outperform" rating and set a $92.00 price objective on shares of LeMaitre Vascular in a report on Friday, September 20th. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Tuesday, August 27th. JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 20th. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price on the stock. Finally, Lake Street Capital started coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They set a "buy" rating and a $105.00 price target for the company. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular currently has an average rating of "Moderate Buy" and a consensus price target of $94.67.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.